Development and clinical study of submicronic-atropine sulphate respiratory fluid as a novel organophosphorous poisoning antidote

References

• Aaltonen L, Kanto J, Iisalo E, Pihlajamäki K. (1984). Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application. Eur J Clin Pharmacol 26: 613–17
   PubMed Web of Science ®Google Scholar
• Albuquerque EX, Pereira EF, Aracava Y, et al. (2006). Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci USA 103:13220–5
   PubMed Web of Science ®Google Scholar
• Ali-Melkkilä T, Kanto J, Iisalo E. (1993). Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 37:633–42
   PubMed Web of Science ®Google Scholar
• Ali R, Jain GK, Iqbal Z, et al. (2009). Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine NBM 5:55–63
   PubMed Web of Science ®Google Scholar
• Ali R, Mittal G, Ali R, et al. (2013). Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases. J Microencapsul 30:546–58
   PubMed Web of Science ®Google Scholar
• Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29:196–212
   PubMed Web of Science ®Google Scholar
• Bajgar J. (2004). Organophosphates nerve agents poisoning: mechanism of action, diagnosis, prophylaxis and treatment. Adv Clin Chem 38:151–216
   PubMed Web of Science ®Google Scholar
• Bentur Y, Layish I, Krivoy A, et al. (2006). Civilian adult self injections of atropine-trimedoxime (TMB4) auto-injectors. Clin Toxicol 44:301–6
   Web of Science ®Google Scholar
• Berghem L, Bergman U, Schildt B, Sörbo B. (1980). Plasma atropine concentrations determined by radioimmunoassay after single-dose i.v. and i.m. administration. Br J Anaesth 52:597–601
   PubMed Web of Science ®Google Scholar
• Bhavna, Ahmad FJ, Mittal G, et al. (2009). Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constructive conditions. Eur J Pharm Biopharm 71:282–91
   PubMed Web of Science ®Google Scholar
• Dequin PF, Faurisson F, Lemarie E, et al. (2001). Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J 18:316–22
   PubMed Web of Science ®Google Scholar
• Dollery C. (1999). Therapeutic drugs. 2nd ed. New York: Churchill Livingstone
   Google Scholar
• Dunn MA, Hackley BE, Sidell FR. (1997). Pretreatment for nerve agent exposure. In: Sidell FR, Takafuji ET, Franz DR, ed. Medical aspects of chemical and biological warfare. Washington: Borden Institute, 181–96
   Google Scholar
• Kehe CR, Lasseter KC, Miller NC, et al. (1992). Comparative absorption of atropine from a metered dose inhaler and an intramuscular injection. Ther Drug Monitor 14:132–4
   PubMed Web of Science ®Google Scholar
• Kumar N, Soni S, Jaimini A, et al. (2011). Edetate calcium disodium nanoparticle dry powder inhalation: a novel approach against heavy metal decorporation. Int J Pharm 416:376–83
   PubMed Web of Science ®Google Scholar
• Mittal G, Kumar N, Rawat H, et al. (2010). A radiometric study of factors affecting drug output of jet nebulizers. Ind J Pharm Sci 72:31–8
   PubMed Web of Science ®Google Scholar
• Newman SP, Clark AR, Talalee N, Clarke SW. (1989). Pressurised aerosol deposition in the human lung with and without an open spacer. Thorax 44:706–10
   PubMed Web of Science ®Google Scholar
• Patel RS, Poddar SS. (2009). Development and characterization of mucoadhesive buccal patches of salbutamol sulphate. Curr Drug Deliv 6:140–4
   PubMedGoogle Scholar
• Pitcairn GR, Newman SP. (1997). Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 10:187–98
   Google Scholar
• Pope C, Karanth S, Liu J. (2005). Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of common mechanism of action. Environ Toxicol Pharmacol 19:433–46
   PubMed Web of Science ®Google Scholar
• Rajpal S, Ali R, Bhatnagar A, et al. (2010). Clinical and bioavailability studies of sublingually administered atropine sulphate. Am J Emerg Med 28:143–50
   PubMed Web of Science ®Google Scholar
• Rajpal S, Mittal G, Sachdeva R, et al. (2009). Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteers. Environ Toxicol Pharmacol 27:206–11
   PubMed Web of Science ®Google Scholar
• Rosman Y, Makarovsky I, Bentur Y, et al. (2009). Carbamate poisoning: treatment recommendations in the setting of a mass casualties event. Am J Emerg Med 27:1117–24
   PubMed Web of Science ®Google Scholar
• Sultana S, Bhatnagar A, Rawat H, et al. (2014). Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation. Pharm Dev Technol 19:623–33
   PubMed Web of Science ®Google Scholar
• Sultana S, Singh T, Ahmad FJ, et al. (2011). Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning. Environ Toxicol Pharmacol 31:436–42
   PubMed Web of Science ®Google Scholar
• Vesela S, Kuca K, Jun D. (2008). Daphnia intoxicated by nerve agent tabun can be treated using human antidotes. Environ Toxicol Pharmacol 25:329–33
   PubMed Web of Science ®Google Scholar
• Volans AP. (1996). Sarin: guidelines on the management of victims of a nerve gas attack. J Accid Emerg Med 13:202–6
   PubMedGoogle Scholar
• Xu A, Havel J, Linderholm K, Hulse J. (1995). Development and validation of an LC/MS/MS method for the determination of l-hyoscyamine in human plasma. J Pharm Biomed Anal 14:33–42
   PubMed Web of Science ®Google Scholar